The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience
Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-11
DOI: 10.2147/dddt.s618596 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Xueting Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Glucocorticoids. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
ORCID-Profile: Ben Ke
Zitieren
APA
Li, X., Zhang, Y., Xu, C., & Ke, B. (2026). The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience. Drug Design, Development and Therapy, Volume 20, 1-11. https://doi.org/10.2147/dddt.s618596
Vancouver
Li X, Zhang Y, Xu C, Ke B. The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience. Drug Design, Development and Therapy. 2026;Volume 20:1-11. doi:10.2147/dddt.s618596
BibTeX
@article{Li2026,
author = {Li, Xueting and Zhang, Yinghui and Xu, Chenyun and Ke, Ben},
title = {The Efficacy and Safety of Telitacicept versus the Recommended Regimens in IgA Nephropathy: A Single-Center Experience},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--11},
doi = {10.2147/dddt.s618596}
}
EUVIMED